Syndax Pharmaceuticals (SNDX) said Monday that it appointed Nicholas Botwood as chief medical officer and head of research and development.
Prior to this role, Botwood has been head of worldwide medical oncology at Bristol Myers Squibb (BMY) since 2022.
He will succeed Neil Gallagher who is departing to pursue other opportunities, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.